WO2010043394A1 - Flacon à bouchon gicleur pour le titrage de produits pharmaceutiques - Google Patents
Flacon à bouchon gicleur pour le titrage de produits pharmaceutiques Download PDFInfo
- Publication number
- WO2010043394A1 WO2010043394A1 PCT/EP2009/007400 EP2009007400W WO2010043394A1 WO 2010043394 A1 WO2010043394 A1 WO 2010043394A1 EP 2009007400 W EP2009007400 W EP 2009007400W WO 2010043394 A1 WO2010043394 A1 WO 2010043394A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage
- dispensing
- kit according
- pharmaceutical
- base
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
- B05B11/1001—Piston pumps
Definitions
- the present invention relates to a pharmaceutical kit comprising (i) a pump dispenser for dispensing multiples of a predetermined base-dosage of a liquid or paste-like pharmaceutical (ii) said liquid or paste-like pharmaceutical contained in said pump dispenser and (iii) instructions for implementing a predetermined titration scheme, wherein said titration scheme comprises the dispensing of at least two different integer multiples of said predetermined base-dosage.
- the present invention also relates to the use of said kit for treating a patient.
- a desired dosage regime and/or a desired overall dosage cannot or should not be achieved in a single step but rather by means of incrementally increasing or decreasing the dosage from a certain predefined initial dosage to a certain predetermined final dosage and/or by means of dosing in intervals.
- Titration packages comprising different tablets of increasing dosages (for example 5 mg, 10 mg, 15 mg, 20 mg) are also known from the art (see, e.g., US 2006/0278557).
- a titration package and method for enabling compliance with a regime of changing dosage of medication over a period of time is provided.
- the solid formulation package includes a backing having an array of receivers with the array including a plurality of columns and a plurality of rows.
- a plurality of sets of tablets are provided with each tablet in set having a common dose of medication and a different dose than a tablet of a different set.
- a solid formulation may not be available or may be difficult to implement.
- manufacturing and providing a large number of different tablets may be cumbersome and ineffective.
- at least four different tablets each having a different composition need to be manufactured and packaged/provided separately.
- a method of dosing liquids known in the art is a droplet dispenser.
- small droplets are dispensed out of a bottle having a comparatively small orifice.
- the volume of the droplet so dispensed is determined, within a certain margin of error, by the geometry of the orifice.
- a large number of droplets needs to be dispensed and counted, for example 20 droplets.
- multiples of a base-dosage would need to be dispensed rendering this system cumbersome and error-prone, for example for elderly and/or impaired patients.
- one object of the present invention is to provide a means for delivering a liquid or paste-like pharmaceutical to a patient in need thereof that allows for a high degree of flexibility in regard to how many and which multiples of a base-dosage can be administered and that allows for easy and safe dispensing of different dosages even if the patient is potentially impaired, for example in regard to vision or in regard to memory.
- Drawbacks and limitations posed by the prior art as discussed above should be avoided or minimized.
- a pharmaceutical kit comprising (i) a pump dispenser for dispensing multiples of a predetermined base-dosage of a liquid or paste-like pharmaceutical (ii) said liquid or paste- like pharmaceutical contained in said pump dispenser and (iii) instructions for implementing a predetermined titration scheme, wherein said titration scheme comprises the dispensing of at least two different integer multiples of said predetermined base-dosage.
- said pump dispenser comprises at least a pump head and dispensing is achieved by means of actuating said pump head of said pump dispenser.
- said pump dispenser comprises at least one pump head and at least one reservoir attached thereto.
- Pump heads are easy to operate and are made, in one embodiment, big enough and ergonomically suitable for operation by elderly patients, visually impaired patients and/or patients who are impaired in regard to motion control.
- the pump head is of the "push-plunger"-type, i.e. comprises at least one plunger or piston or actuated pusher, i.e. actuator, and at least one sealed chamber in which a pressure can be built up by means of moving said plunger/piston/ actuator.
- said pump dispenser comprises at least one hollow body with a chamber of a defined inner volume and a defined inner diameter.
- said hollow body comprises a recess that has a diameter that is larger than said inner diameter of the chamber.
- said pump dispenser additionally comprises at least one ball acting as a one-way valve and at least one piston that runs inside said hollow body.
- the volume as defined by the chamber inside said hollow body of the dispenser head is more than 0.1 ml or more than 0.5 ml or more than 1 ml or more than 3 ml. In accordance with another embodiment, said volume ranges from 0.1 ml to 5.0 ml or from 0.3 ml to 3 ml or from 0.5 ml to 1 ml.
- the spout of the pump dispenser i.e. the part of the pump head out of which the liquid or paste-like pharmaceutical is ultimately expelled is arcuate, i.e. has at least one portion that is substantially parallel to the horizontal plane and has at least one other portion that is inclined in at least a 45 degree angle relative to said horizontal plane.
- the dispensing of the base-dosage is achieved by performing one stroke of an actuator or plunge or piston of the pump head.
- one stroke means one single stroke.
- said liquid or paste-like pharmaceutical comprises at least one NMDA receptor antagonist and/or at least one acetylcholinesterase inhibitor and/or at least one ⁇ g/ ⁇ io nicotinic receptor antagonist.
- said liquid or paste-like pharmaceutical comprises at least memantine and/or neramexane and/or pharmaceutically acceptable salts thereof such as memantine HCI or neramexane mesylate.
- said titration scheme comprises at least one up-titration step, i.e. comprises the dispensing of at least two or at least three or at least four increasing integer multiples of said predetermined base-dosage, for example the dispensing of at least two increasing integers of the base-dosage with said integer starting at 1.
- said titration scheme comprises the dispensing of at least two or at least three or at least four decreasing integer multiples of said predetermined base-dosage.
- Such a titration scheme may be used for decreasing the dosage to a certain predetermined final dosage (such as for a maintenance therapy).
- the scheme may comprise at first the dispensing of an integer multiple ni of a base-dosage and consecutively dispensing an integer multiple n 2 , wherein
- said titration scheme comprises the dispensing of at least two or at least three or at least four alternating dosages that are different from each other.
- Such a titration scheme may be used for alternating between certain predetermined dosages (such as for an interval therapy).
- each of the at least two different dosages are dispensed at least twice.
- an initial dosage may be administered for several consecutive days, including one week or more than a week, for example once daily for one week, before the next (different) dosage is administered, for example a higher or a lower or an alternating dosage, also for example once daily for one week.
- the kit as described in any one of the aforementioned embodiments is used for the treatment of a patient.
- "dispensing” means “actuating a pump dispenser”. This is achieved, in one embodiment, by means of actuating the pump head of the pump dispenser, for example by performing one complete or one incomplete stroke of the actuator or plunge or piston of the pump head.
- “one” means “one single”.
- predetermined base-dosage means one specific volume that is dispensed per (incomplete or complete) stroke, for example 0.25 ml or 0.3 ml or 0.5 ml or 1 ml or 2 ml or 3 ml or 5 ml. This volume is defined by the geometry of the pump dispenser, for example of the pump head and the volume of the hollow chamber formed therein. Said predetermined base-dosage cannot be adjusted or altered by the patient.
- an incomplete stroke of the actuator or plunge or piston of the pump head may also be sufficient, as long as the amount of fluid dispensed per (incomplete) stroke is the same or similar.
- titration occurs in at least two steps of administering consecutively increasing multiple integers of the base-dosage.
- Such a titration regime is referred to as "up-titra- tion” and may be used, for example, for administering memantine as the active ingredient.
- said integer is starting at 1 , i.e. one time the base-dosage is administered, then two times the base-dosage etc.
- titration occurs in at least two steps of administering consecutive decreasing multiple integers of a base-dosage.
- the starting dosage may be 100 %, i.e. 4 times the base-dosage of 25 % while the following dosage is 75 %, i.e. 3 times the base-dosage of 25 %.
- Such a titration regime is referred to as "maintenance therapy" and may be used, for example, for administering neramexane or pharmaceutically acceptable salts thereof.
- titration occurs in at least three steps of administering consecutive multiple integers of the base-dosage.
- said integer starts at 1 and the dosage increases (i.e. 1 time the base-dosage, 2 times the base- dosage, 3 times the base-dosage, ...), while in another embodiment, the integer starts at a number ⁇ 3 and the dosage decreases (i.e. 3 times the base- dosage, 2 times the base-dosage, 1 time the base-dosage).
- titration occurs in at least four steps of administering consecutive multiple integers of the base-dosage with said integer starting at 1 (i.e. 1 time the base-dosage, 2 times the base-dosage, 3 times the base-dosage, 4 times the base-dosage or 4 times the base-dosage, then 3 times the base-dosage etc.), while in another embodiment, the integer starts at a number ⁇ 4 and the dosage correspondingly decreases.
- titration occurs in intervals with a high dosage and a subsequent lower dosage followed again by said high dosage etc.
- a practitioner prescribing the kit may devise individual titration schemes for individual patients while using one pump dispenser provided with one base-dosage that can therefore be manufactured and provided commercially at minimum operating expenses.
- Liquid or paste-like pharmaceuticals according to the present invention may be in the form of a solution, a dispersion or an emulsion (micro- or nano- emulsions, self-emulsifying system, multiple emulsions) or in the form of a gel, paste, suspension (micro- or nano-suspension), hydrosol, liposome, mixed micells or in other forms of colloidal disperse systems such as drug loaded microparticles, nanocapsules or nanoparticles dispersed in a colloidal system or solution.
- Paste-like masses may display a Newtonian or a non- Newtonian flow behaviour.
- Active pharmaceutical ingredients that may be administered in accordance with such a titration scheme are or may be the following active ingredients in liquid or in paste-like form: uncompetitive channel blockers (e.g. NMDAr antabonists, e.g. amantadine, dextromethorphan, ibogaine, ketamine, phencyclidine, riluzole, memantine, neramexane), antagonists at ⁇ g/cho nicotinic receptors (e.g. neramexane), non-competitive antagonists (e.g. dizocilpine, aptiganel, remacimide), glycine antagonists (e.g.
- NMDAr antabonists e.g. amantadine, dextromethorphan, ibogaine, ketamine, phencyclidine, riluzole, memantine, neramexane
- ACPC 1-aminocyclopropanecarboxylic acid
- competitive antagonists e.g. AP7 (2-amino-7-phosphonoheptanoic acid)
- thrombolytics e.g. reteplase, tenecteplase, anistreplase, streptokinase, urokinase
- anticoagulants e.g. heparin, warfarin, acenocoumarol, phenprocoumon, phenindione, argatroban, lepirudin, bivalirudin
- antibiotics corticosteroids
- clomethasone be- clomethasone, budesonide, betamethasone, ciclesonide, flunisolide, fluticasone, mometasone, refleponide, triamcinolone), antiplatelet agents (e.g. aspirin, clopidogrel, ticlopidine, abciximab, eptifibatide, tirofiban, cilostazol), non-stereoidal anti-inflammatories (NSAID) (e.g. salicylates (e.g.
- arylalkanoic acids e.g. diclofenac, aceclofenac, acemetacin, bromfenac, etodolac, indometacin, nabumetone, sulindac, tometin
- 2-Arylpropionic acids profens
- ibuprofen carprofen, fenbufen, fenoporfen, flurbiprofen, ketoprofen, ketorolac, loxoprofen, naproxen, oxaprozin, tiaprofenic acid, suprofen), N-Arylanthranilic acids (fenamic acids) (e.g. mefenamic acid, meclofenamic acid), pyrazolidine derivates (e.g. phenylbutazone, azapropa- zone, metamizole, oxyphenbutazone, sulfinpyrazone), oxicams (e.g.
- COX-2 inhibitors e.g. celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, valdecoxib
- sulphonanilides e.g. nimesulide
- growth factors e.g.
- TGF- ⁇ transforming growth factor beta
- G-CSF granulocyte-colony stimulating factor
- GM-CSF granulocyte-macrophage colony stimulating factor
- NGF nerve growth factor
- PDGF platelet derived growth factor
- EPO erythropoietin
- TPO throm- bopoietin
- GDF-8 growth differentiation factor-9
- aFGF or FGF-1 acidic fibroblast growth factor
- bFGF or FGF-2 basic fibroblast growth factor
- EGF epidermal growth factor
- HGF hepatocyte growth factor
- immunosuppressant drugs e.g.
- cyclosporine tacrolimus, prednisolone, azathioprine, sirolimus, mycopehnolate, glatiramer acetate
- antineoplastic agents alkylating agents (e.g. cisplatin, carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil), anti-metabolites (e.g. azathioprine, mercaptopurine, pyrimidine), vinca alkaloids (e.g. vincristine, vinblastine, vinorelbine, vindesine), podophyllotoxin (e.g.
- etoposide, teni- poside taxanes (e.g. paclitaxel), topoisomerase inhibitors (e.g. amsacrine, etoposide, etoposide phosphate, teniposide, camptothecins such as iri- notecan, topotecan), antitumor antibiotics (e.g. dactinomycin), monoclonal antibodies (e.g. trastuzumab, cetuximab, rituximab, bevacizumab)), ACE- inhibitors (e.g.
- captopril zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, fosinopril
- Acetylcholinesterase Inhibitors e.g. done- pezil, rivastigmine, pyridostigmine, tetrahydroaminoacridine physostigmine, galantamine, tacrine, edrophonium, neostigmine
- HMG-coA reductase inhibitors e.g.
- atorvastatin cerivastatin, fluvastatin, lovastatin, pravastatin, simvastatin
- beta-blockers e.g. alprenolol, carteolol, levobunolol, mepin- dolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, acebutolol, atenolol, betaxolol, bisoprolol, esmolol, metoprolol, nebivolol, carvedilol, celiprolol, lavetalol, butaxamin), calcium channel blockers (e.g.
- nimodipine amlodi- pine, felodipine, nicardipine, nifedipine, nisoldipine, nitrendipine, lacidipine, lercandipine
- long acting nitrates e.g. isosorbide dinitrate and mononitrate, nitroglycerin
- cholesterol-lowering agents e.g. bezafibrate, ciprofibrate, clofibrate, gemfibrozil, fenofibrate.
- the kit comprising a liquid or paste-like pharmaceutical comprises at least one NMDA receptor antagonist.
- NMDAr antagonists may be compositions com- prising, as pharmaceutically active ingredients, memantine or neramexane or pharmaceutically acceptable salts thereof.
- kits comprising a liquid or paste-like pharmaceutical comprising at least one acetylcholinesterase inhibitor (AchEI).
- acetylcholinesterase inhibitors may be compositions comprising, among others, donepezil, rivastigmine, pyridostigmine, tetrahydroaminoacridine, physostigmine, galantamine, tacrine, edrophonium, neostigmine and pharmaceutically acceptable salts thereof.
- the fluid, liquid or paste-like substance may include any other solvent, solute, additive, adjuvant or excipient that is pharmaceutically acceptable.
- solvent(s) water and alcohol, or mixtures thereof, are used as solvent(s).
- Pump dispensers for dispensing liquids, viscous or paste-like masses, for example soap, lotion or condiments are known form the art.
- a simple-to- operate push plunger housed in a container is known, for example, from US 3 463 093.
- Another example of a general use dispensing unit is given in US 5 326 000.
- a dispenser or delivery apparatus for flowable media, particularly very viscous or gel-like media, specifically also comprising pharmaceuticals is disclosed in US 4 728 008.
- the pump dispenser comprises at least one pump head and at least one reservoir attached thereto.
- the pump head is of the "push-plunger"-type, i.e. comprises at least one plunger or piston or actuated pusher (actuator) and at least one sealed chamber in which a pressure can be built up by means of moving said plunger/piston/actuator.
- Dispensing by means of the "push-plunger"-principle is seen as particularly advantageous for operation of the dispenser by visually impaired patients or patients having coordination/motion control issues as is typical for some of the indications in accordance with the present invention, for example dementia, glaucoma, Alzheimer's disease etc.
- Droplet dispensers for liquids as known from pharmaceutical applications employing measuring spoons and/or narrow spouts for "counting" droplets are much less suitable for these indications/applications than the pump dispenser and kit in accordance with the present invention.
- the pump dispenser dispenses said predetermined base-dosage essentially independent of the actuation path, and/or irrespective of how far the pump head has been actuated.
- the amount of dispensed fluid is independent of how far the pump head (or, more specifically, the plunger) has been actuated once a predetermined threshold of the actuation path has been passed.
- said threshold is defined by a recess in a chamber of the pump head of the dispenser.
- the pump head comprises at least one hollow body (15) with a chamber (19) of a given inner diameter di 5 .
- This chamber contains the substance to be dispensed during the next cycle.
- This hollow body (15) also comprises a recess (20) with a diameter larger than di 5 .
- the hollow body furthermore comprises a conical seat and a second channel (22). This second channel is connected to a larger reservoir of the substance to be dispensed, i.e. the reservoir of the overall dispenser.
- a ball (21) is located in a conical seat of hollow body (15). Said ball (21) acts as a one-way valve and may seal off the second channel (22). Inside the hollow body (15) runs a piston (17) with a hollow stem (18) and an elastic lip at the lower end of piston (17).
- the hollow stem (18) comprises a first channel (27).
- a first spring (24) is provided between piston (17) and a shoulder of the hollow body (15). Said first spring (24) drives the piston away from the above-discussed reservoir.
- the hollow stem (18) has a compartment at its top to house the cone (28) and a second spring (29). This small compartment is open (35) to lead to any tube or applicator or spout for actually dispensing the fluid. Cone (28) is loaded by this second spring (29) and will close channel (27). Further details can be taken from Figure 1.
- the cycle of dispensing the substance and refilling chamber (19) can be achieved as follows. Initially, chamber (19) is filled with the pharmaceutical substance to be dispensed. Springs (24) and (29) are not fully expanded. The second and first channels (22) and (27) are closed. The dispensing cycle is started by pushing the stem (18) into the hollow body (15). Meanwhile, piston (17) is driven further into the hollow body (15) thus increasing the chamber pressure. At the same time, spring (24) is being compressed.
- the second spring (29) yields to said chamber pressure.
- This "yielding" can be adjusted (or "predetermined") by choosing an appropriate second spring (29).
- the cone (28) opens the first channel (27).
- the pharmaceutical substance now flows out of chamber (19) through first channel (27) and opening (35), driven by the chamber pressure.
- the elastic lower lip of piston (17) reaches the recess (20) the chamber pressure collapses.
- the dose (volume) of the supplied substance is determined by the inner diameter dis of hollow body (15) and the distance covered by piston (17) before reaching the annular recess (20).
- first spring (24) will push piston (17) upwards along the hollow body (15). On its way up the elastic lower lip of piston (17) will exit the annular recess (20) and reengage with the inner diameter of the chamber (19) thus sealing said chamber. Further travel of piston (17) causes the chamber pressure to drop further.
- the reduced chamber pressure allows ball (21) to leave its conical seat, i.e. opens up the seal.
- the reduced chamber pressure draws fresh liquid or paste from the large reservoir into chamber (19) until the shoulder of stem (18) makes contact with bar (52). This contact of stem (18) and the bar (52) ends the cycle of operation.
- the pump dispenser for dispensing multiples of a predetermined base-dosage of a liquid or paste-like pharmaceutical comprises at least one pump head comprising a hollow body with a chamber of a defined inner volume and a defined inner diameter, wherein the hollow body further comprises a recess that has a diameter that is larger than said inner diameter of the chamber.
- the overall dispensed volume per stroke i.e. the volume of the predetermined base- dosage
- the volume as defined by the chamber inside the hollow body of the dispenser head is more than 0.3 ml, more than 0.5 ml or more than 1 ml.
- the concentration of the active ingredient in said predetermined dispensed volume is comparatively low, for example lower than 50 % (by volume), lower than 10 % or lower than 5 % or lower than 1 %.
- concentration of the active ingredient in said predetermined dispensed volume is comparatively low, for example lower than 50 % (by volume), lower than 10 % or lower than 5 % or lower than 1 %.
- 5 mg of active ingredient may be present in a base-dosage of 0.5 ml (resulting in a 1 % solution).
- any possible variation in dispensed volume per successive stroke translates only into a small variation in dispensed active ingredient, i.e. in base-dosage.
- Commonly used droplet bottles for dispensing liquid pharmaceuticals comprise a particularly narrow opening or spout through which only small droplets can be expelled. Due to the geometric constraint of the small opening and the action of surface tension, the volume of these small droplets is comparatively constant, albeit very small. In order to compensate for volume fluctuations and in order to achieve a final volume that can be reasonably administered, for example in a spoon, a large number of these small droplets needs to be dispensed in order to arrive at the one pre- described dosage, for example 20 droplets or 30 droplets.
- This administration scheme has a couple of draw-backs, in particular the requirement to count a large number of droplets. Therefore, such an administration scheme is not suitable for patients that are physically and/or mentally impaired.
- the presently described pump-dispenser is designed to have an easy-to-use actuation head (as known, for example, from everyday usage soap dispensers) while dispensing the required base-dosage in one stroke.
- an easy-to-use actuation head as known, for example, from everyday usage soap dispensers
- this may be achieved in the comparatively small number of two or three strokes (using a droplet-based dispenser as described above, for example the dispensing of two or three times 20 droplets would be required to achieve the same result).
- the spout of the pump dispenser i.e. the part of the pump head out of which the liquid, viscous or paste-like pharmaceutical is ultimately expelled is arcuate, i.e. has at least one portion that is substantially parallel in the horizontal direction and has at least one portion that is inclined in at least a 45 degree angle relative to the horizontal plane.
- This arcuate spout allows for a less spill-prone dispensing and is of particular advantage if the user of the dispenser is an older, handicapped or visually impaired patient.
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un kit pharmaceutique qui comporte (i) un flacon à bouchon gicleur destiné à distribuer de multiples dosages de base prédéterminés d'un produit pharmaceutique liquide ou de type pâte; (ii) ledit produit pharmaceutique liquide ou de type pâte est contenu dans ledit flacon à bouchon gicleur, et (iii) des instructions de mise en œuvre d'un schéma de titrage prédéterminé, ledit schéma de titrage comportant la distribution d'au moins deux multiples entiers dudit dosage de base prédéterminé. La présente invention concerne également l'utilisation d'un tel kit pour le traitement d'un patient.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19631308P | 2008-10-16 | 2008-10-16 | |
EP08018154 | 2008-10-16 | ||
US61/196,313 | 2008-10-16 | ||
EP08018154.8 | 2008-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010043394A1 true WO2010043394A1 (fr) | 2010-04-22 |
Family
ID=40510395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/007400 WO2010043394A1 (fr) | 2008-10-16 | 2009-10-15 | Flacon à bouchon gicleur pour le titrage de produits pharmaceutiques |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2177275A1 (fr) |
WO (1) | WO2010043394A1 (fr) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4565302A (en) * | 1983-01-22 | 1986-01-21 | Ing. Erich Pfeiffer Gmbh & Co. Kg | Actuatable dosing mechanism |
US5918568A (en) * | 1996-08-26 | 1999-07-06 | Pharmalett Denmark A/S | Method of medicating and individualizing treatment shampoo for dermatological disturbances of companion animals |
US20020066752A1 (en) * | 2000-10-16 | 2002-06-06 | Stefan Ritsche | Dispenser and method for discharging media |
US6605060B1 (en) * | 1995-06-07 | 2003-08-12 | O'neil Alexander George Brian | Patient controlled drug delivery device |
US20040050858A1 (en) * | 2002-07-13 | 2004-03-18 | Aero Pump Gmbh | Double-acting pump for ejecting a product from a container |
US20040135002A1 (en) * | 2001-04-30 | 2004-07-15 | Klaus-Dieter Beller | Device for the spraying of fluids |
US20070275145A1 (en) * | 2006-05-26 | 2007-11-29 | Catani Steven J | Method of delivering a high intensity sweetener to a liquid foodstuff |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1302372C2 (de) | 1967-01-17 | 1978-06-08 | Pfeiffer Zerstäuber-Vertriebsgesellschaft mbH & Co KG, 7760 Radolfzell | In einem gefaess eingebaute einfachwirkende handbetaetigte schubkolbenpumpe |
DE3530486A1 (de) | 1985-08-27 | 1987-03-05 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung fuer fliessfaehige medien |
DE4108646A1 (de) | 1991-03-16 | 1992-09-17 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung fuer medien |
US7086532B2 (en) | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
-
2009
- 2009-10-15 EP EP09013034A patent/EP2177275A1/fr not_active Ceased
- 2009-10-15 WO PCT/EP2009/007400 patent/WO2010043394A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4565302A (en) * | 1983-01-22 | 1986-01-21 | Ing. Erich Pfeiffer Gmbh & Co. Kg | Actuatable dosing mechanism |
US6605060B1 (en) * | 1995-06-07 | 2003-08-12 | O'neil Alexander George Brian | Patient controlled drug delivery device |
US5918568A (en) * | 1996-08-26 | 1999-07-06 | Pharmalett Denmark A/S | Method of medicating and individualizing treatment shampoo for dermatological disturbances of companion animals |
US20020066752A1 (en) * | 2000-10-16 | 2002-06-06 | Stefan Ritsche | Dispenser and method for discharging media |
US20040135002A1 (en) * | 2001-04-30 | 2004-07-15 | Klaus-Dieter Beller | Device for the spraying of fluids |
US20040050858A1 (en) * | 2002-07-13 | 2004-03-18 | Aero Pump Gmbh | Double-acting pump for ejecting a product from a container |
US20070275145A1 (en) * | 2006-05-26 | 2007-11-29 | Catani Steven J | Method of delivering a high intensity sweetener to a liquid foodstuff |
Also Published As
Publication number | Publication date |
---|---|
EP2177275A1 (fr) | 2010-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10300212B2 (en) | Multiple dosage injector | |
JP6337084B2 (ja) | 流体ディスペンサー装置 | |
KR101923331B1 (ko) | 약물 분배 장치 및 방법 | |
RU2562982C2 (ru) | Выходная насадка для дозатора | |
HRP20210968T1 (hr) | Postupak primjene tekućih analgetika | |
RU2007101686A (ru) | Комбинированная композиция | |
CN112138250B (zh) | 保持给药均一度的药物流体分配器及右美托咪定鼻喷器 | |
EP3164121A1 (fr) | Thérapies par association médicamenteuse contre le cancer et leurs procédés de fabrication et d'utilisation | |
EP3618782B1 (fr) | Distributeur de goutte | |
JP2012504999A5 (fr) | ||
WO2009086009A1 (fr) | Compteurs de doses et contenants | |
JP6875502B2 (ja) | 発泡性組成物、エアゾール製品、及び皮膚への感覚的な利益を改善するためのそれらの使用方法 | |
EP2177275A1 (fr) | Distributeur à pompe pour le titrage de produits pharmaceutiques | |
US20030044432A1 (en) | Acne treating composition | |
US20140203097A1 (en) | Selectively dispensing sprays | |
JP2010538066A5 (fr) | ||
RU2011139637A (ru) | Сублингвальная спреевая композиция, содержащая дигидроартемизинин | |
US10709663B2 (en) | Mupirocin cream in pump device | |
CA2756761C (fr) | Conditionnement a doses multiples permettant de distribuer des doses multiples predefinies d'un produit pharmaceutique, cure et methode de traitement | |
WO2001091726A1 (fr) | Composition pour le traitement de l'acne | |
EP2942050A1 (fr) | Composition huileuse pulvérisable à base de vitamines liposolubles du groupe d et son utilisation | |
WO2009134129A1 (fr) | Dispositif pour contenir et distribuer de façon dosée au moins un fluide | |
EP2526925A1 (fr) | Une pompe de pulvérisation ou pompe aérosol à voie orale et à dose reglable comprenant mémantine | |
US11946788B2 (en) | Airless metered fluid dispenser assembly | |
JP2018108963A (ja) | 液状口腔咽喉薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09737361 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09737361 Country of ref document: EP Kind code of ref document: A1 |